Q1 EPS Estimates for USANA Health Sciences Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA) – Investment analysts at Sidoti Csr dropped their Q1 2025 earnings per share estimates for USANA Health Sciences in a research report issued to clients and investors on Thursday, April 17th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.70 for the quarter, down from their prior forecast of $0.71. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.67 EPS, FY2025 earnings at $2.59 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.39 EPS.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Several other equities research analysts have also commented on the stock. DA Davidson cut their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Trading Up 1.3 %

USNA stock opened at $23.75 on Friday. The stock has a market cap of $448.90 million, a P/E ratio of 8.39, a PEG ratio of 0.93 and a beta of 1.00. USANA Health Sciences has a twelve month low of $23.26 and a twelve month high of $49.78. The company’s 50 day moving average is $28.59 and its two-hundred day moving average is $33.66.

Insider Activity at USANA Health Sciences

In other news, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joshua Foukas sold 5,732 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders sold a total of 15,920 shares of company stock worth $500,285 in the last 90 days. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of USNA. Pzena Investment Management LLC increased its stake in shares of USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock worth $39,015,000 after acquiring an additional 37,466 shares during the period. Dimensional Fund Advisors LP boosted its holdings in USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock valued at $27,751,000 after purchasing an additional 55,059 shares in the last quarter. Pacer Advisors Inc. increased its position in USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock worth $21,247,000 after purchasing an additional 47,745 shares during the period. State Street Corp raised its stake in shares of USANA Health Sciences by 0.6% during the 3rd quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after buying an additional 2,782 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of USANA Health Sciences by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 301,949 shares of the company’s stock valued at $10,839,000 after buying an additional 4,829 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.